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Abstract
Introduction Etomidate blocks adrenocortical synthesis when it
is administered intravenously as a continuous infusion or a single
bolus. The influence of etomidate administration on the
incidence of relative adrenal insufficiency in patients with septic
shock has not been formally investigated. The objective of this
study was to determine the incidence of relative adrenal
insufficiency in patients with septic shock after etomidate
administration compared with patients with septic shock who
did not receive etomidate.
Methods In this retrospective study, 152 adults with septic
shock who had a consyntropin stimulation test between March
2002 and August 2003 in a tertiary medical center were
included. Relative adrenal insufficiency was defined as a rise in
serum cortisol ≤ 9 µg/dl after the administration of 250 µg of
consyntropin. Patients were divided into those who did and
those who did not receive etomidate before the stimulation test.
The proportion of patients with relative adrenal insufficiency in
these two groups was compared using Fischer's exact test. A P
of value < 0.05 was considered statistically significant.
Results The mean age of the patients was 64 years, 59% of
patients were male, 97% of patients were white and their
hospital mortality rate was 57%. Thirty-eight patients (25%)
received etomidate before the cosyntropin stimulation test, and
the median (interquartile range) time interval between the
administration of the drug and the test was 7 (4–10) hours. The
incidence of relative adrenal insufficiency was 76% in the
patients who received etomidate compared with 51% in the
patients who did not (P = 0.0077).
Conclusion The incidence of relative adrenal insufficiency in
patients with septic shock is increased when the stimulation test
is performed after the administration of etomidate.
Introduction
Relative adrenal insufficiency, defined as a blunted increase in
cortisol levels after stimulation with adrenocorticotrophic hor-
mone, is common in patients with septic shock [1], and
replacement therapy with hydrocortisone and fludrocortisone
has been shown to reduce the risk of death in this setting [2].
Etomidate, an induction agent widely used to facilitate
endotracheal intubation, is an imidazole derivative that revers-
ibly blocks adrenocortical synthesis when administered intra-
venously as a continuous infusion or a single bolus [3]. A
single dose of etomidate is a major risk factor for the develop-
ment of relative adrenal insufficiency for at least 24 hours after
its administration [4]. Because most patients with septic
shock require endotracheal intubation, and the influence of
etomidate administration on the incidence of relative adrenal
insufficiency in patients with septic shock has not been for-
mally investigated, the objective of this study was to determine
the incidence of relative adrenal insufficiency in patients with
septic shock after etomidate administration. We hypothesised
that the administration of etomidate increases the incidence of
relative adrenal insufficiency in patients with septic shock.
Materials and methods
In this retrospective study, we first identified 1,207 consecu-
tive patients who had their serum cortisol level measured at
the Mayo Clinic (Rochester, MN, USA) between March 2002
and August 2003. The records of these patients were
reviewed. Only adults with septic shock who had a short
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cosyntropin stimulation test were included in this study. In this
test, cortisol levels were measured immediately before and
both 30 minutes and 60 minutes after the administration of
cosyntropin (250 µg). The cortisol response was calculated as
the difference between the highest and the lowest cortisol lev-
els measured before and after the administration of cosyntro-
pin. Relative adrenal insufficiency was defined as a rise in
serum cortisol ≤ 9 µg/dl [1]. Septic shock was defined accord-
ing to the American College of Chest Physicians/Society of
Critical Care Medicine Consensus Conference Committee cri-
teria [5]. Patients were excluded if they had received corticos-
teroids or ketoconazole before the cosyntropin stimulation
test, or if they had an adrenal or pituitary disorder. The Mayo
Foundation Institutional Review Board approved the study,
and a waiver of informed consent was granted. Patients who
did not authorize their medical records to be reviewed for
research were excluded. Data collected included demograph-
ics, the results of the cosyntropin stimulation test, the use of
etomidate, the time interval between the etomidate administra-
tion and the cosyntropin stimulation test, the presence of rela-
tive adrenal insufficiency, the use of corticosteroids or
ketoconazole before the test and the presence of adrenal or
pituitary disorders. Descriptive data were summarized as
mean (± standard deviation (SD)), median (with interquartile
range (IQR)) or percentages. Patients were divided into those
who did and those who did not receive etomidate before the
cosyntropin stimulation test. The student's t test, the Mann-
Whitney U test and Fischer's exact test were used for compar-
isons between groups. The 95% confidence intervals (95%
CI) were calculated, as needed. A P value < 0.05 was consid-
ered statistically significant.
Results
Among the 1,207 patients who had their cortisol level meas-
ured, 163 patients with septic shock had a cosyntropin stimu-
lation test. After excluding 10 patients who had received
corticosteroids before the test and one patient who had an
adrenal tumor, 152 patients were included in this study.
The mean age (± SD) of the patients was 64 (± 17) years,
59% of patients were male and 97% of patients were white.
None of the patients had received ketoconazole or had history
of a pituitary disorder. The hospital mortality rate was 57%.
Thirty-eight patients (25%) received etomidate before the
cosyntropin stimulation test. The median (IQR) time interval
between the administration of the drug and the test was 7 (4–
10) hours. No significant difference in the baseline character-
istics was found in the patients who received etomidate com-
pared with those who did not (Table 1). The incidence of
relative adrenal insufficiency was 76% (95% CI, 67–87%) in
patients who received etomidate compared with 51% (95%
CI, 42–60%) in patients who did not receive etomidate (P =
0.0077; Table 1).
Discussion
In this study, three-quarters of the patients with septic shock
who received etomidate had relative adrenal insufficiency
compared with only half of the patients with septic shock who
did not receive etomidate.
A previous study showed that 54% (95% CI, 47–61%) of
patients with septic shock had relative adrenal insufficiency
[1], which is similar to our findings. In critically ill patients, a sin-
gle dose of etomidate suppresses adrenal function for approx-
imately 24 hours [4,6]. Not surprisingly, we found that 76%
(95% CI, 67–87%) of our patients with septic shock had rela-
tive adrenal insufficiency when tested after the administration
of etomidate. Interestingly, in the study by Annane et al. [2], in
which low doses of hydrocortisone and fluodrocortisone
reduced the risk of death in patients with septic shock and rel-
ative adrenal insufficiency, 72 patients received etomidate pre-
ceding the stimulation test. Of these 72 patients, 68 patients
(94%) had relative adrenal insufficiency [2,7].
Our study has some limitations. It was performed in a single
tertiary medical center and has a retrospective design. Moreo-
ver, the number of patients who received etomidate was rela-
Table 1
Differences between patients with septic shock who did and did not receive etomidate
Etomidate (n = 38) No etomidate (n = 114) P
Mean age (± SD), years 63 (± 18) 65 (± 17) 0.5321
Male gender, n (%) 20 (53) 69 (61) 0.4487
White, n (%) 37 (97) 111 (97) 1.0000
Hospital mortality rate, n (%) 24 (63) 63 (55) 0.4517
Median baseline cortisol level (IQR), µg/dl 32 (23–45) 26 (20–42) 0.3492
Median 30-minute cortisol level (IQR), µg/dl 36 (26–47) 36 (26–53) 0.7642
Median 60-minute cortisol level (IQR), µg/dl 38 (28–52) 41 (28–57) 0.6674
Relative adrenal insufficiency, n (%) 29 (76) 58 (51) 0.0077
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tively small. The smallness of the sample size might account for
absence of statistically significant differences in some of the
variables, including baseline serum cortisol level and hospital
mortality rate, between patients who did and did not receive
etomidate. In spite of these limitations, our findings highlight
the importance of the ongoing controversies and discussions
about the use of etomidate as an induction agent for endotra-
cheal intubation in the intensive care unit, particularly in
patients with septic shock, because of the high frequency of
relative adrenal insufficiency provoked by this medication
[3,8,9]. Two alternative approaches have been proposed to
resolve the etomidate controversy. One option is to eliminate
the use of etomidate altogether in patients with septic shock,
and use alternative agents [3,9]. The second option is to start
treatment with corticosteroids after the administration of eto-
midate [3,8]. Whether there is a real need to test for adrenal
insufficiency, on the basis that our study shows that most
patients with septic shock had relative adrenal insufficiency
after the administration of etomidate, and what dose of corti-
costeroids should be administered are questions that must be
studied in prospective trials.
Conclusion
Relative adrenal insufficiency is present in most patients with
septic shock after the administration of etomidate. Caution is
recommended when using etomidate in these patients.
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Key messages
•  Etomidate reversibly blocks adrenocortical synthesis 
when administered intravenously as a continuous infu-
sion or a single bolus.
•  The majority of patients with septic shock show evi-
dence of relative adrenal insufficiency when the cosyn-
tropin stimulation test is performed within 24 hours of 
the administration of etomidate.